NCT05759923View on ClinicalTrials.gov

First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 26, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Ovarian CarcinomaAdvanced Renal Cell CarcinomaAdvanced Pancreatic CarcinomaAdvanced Colorectal CarcinomaMetastatic Pancreatic CarcinomaMetastatic Colorectal CarcinomaMetastatic Renal Cell CarcinomaMetastatic Ovarian Carcinoma
Interventions
DRUG

OATD-02

Boin Design Scheme will be applied for dose escalation. Dose will start with 2.5mg o.d., the desicion about dose escalations will be made based on the occurence of DLT

Trial Locations (3)

85796

RECRUITING

Site, Bydgoszcz

05-400

RECRUITING

Site, Otwock

01748

RECRUITING

SIte, Warsaw

Sponsors

Lead Sponsor

Molecure S.A.
All Listed Sponsors
lead

Molecure S.A.

INDUSTRY

NCT05759923 - First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours | Biotech Hunter | Biotech Hunter